Drugs / BHV-1300
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06980649 | Aug 2025 → Sep 2027 expected | Graves disease | Biohaven Therapeutics Ltd. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07661056 | Jun 2026 → Jan 2028 expected | Graves disease | Biohaven Therapeutics Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BHV-1300 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07661056 ↗ |
| Route | Subcutaneous | “BHV-1300 is delivered subcutaneously (SC)” NCT06980649 ↗ |